RayKnowChina Research Map
Shortlist0

RecruitingNeuromyelitis optica spectrum disorderPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

An open trial on neuromyelitis optica spectrum disorder, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 27 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 27

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page
  2. Study siteBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page
  3. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  4. Study siteFirst Affiliated Hospital of Fujian Medical University福建医科大学附属第一医院FuzhouHospital page
  5. Study siteFirst Affiliated Hospital of Kunming Medical University昆明医科大学第一附属医院KunmingHospital page
  6. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  7. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  8. Study siteFirst Affiliated Hospital of Wenzhou Medical University温州医科大学附属第一医院WenzhouHospital page
  9. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  10. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  11. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  12. Study siteFirst Hospital of Shanxi Medical University山西医科大学第一医院TaiyuanHospital page
  13. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  14. Study sitePeking University First Hospital北京大学第一医院BeijingHospital page
  15. Study siteQilu Hospital of Shandong University山东大学齐鲁医院JinanHospital page
  16. Study siteSecond Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院HefeiHospital page
  17. Study siteSecond Affiliated Hospital of Harbin Medical University哈尔滨医科大学附属第二医院HarbinHospital page
  18. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  19. Study siteSecond Hospital of Hebei Medical University河北医科大学第二医院ShijiazhuangHospital page
  20. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  21. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  22. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  23. Study siteThird Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院GuangzhouHospital page
  24. Study siteTianjin Medical University General Hospital天津医科大学总医院TianjinHospital page
  25. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  26. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  27. Study siteZhongshan Hospital, Xiamen University厦门大学附属中山医院XiamenHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06413654, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. The blood pregnancy tests were negative within 7 days before the first dose in fertile female subjects. The fertile subjects and the male subjects whose partner are fertile woman agree to use reliable contraception during the study period and within 6 months after the study drug discontinuation;

    Inclusion criterion 3

    Received anti-CD20 or other cell depletion therapy within 6 months before first dose;

    Exclusion criterion 3

    Subjects who had undergone major surgery within 2 months prior to screening or were scheduled to undergo major surgery during the trial;

    Exclusion criterion 8

  3. Pregnant or lactating women; Subjects with birth plans during the trial;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06413654, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Confirmed NMOSD patients;
  • Experienced at least 1 recurrence of NMOSD within 1 year or at least 2 recurrence within 2 years prior to screening;
  • The blood pregnancy tests were negative within 7 days before the first dose in fertile female subjects. The fertile subjects and the male subjects whose partner are fertile woman agree to use reliable contraception during the study period and within 6 months after the study drug discontinuation;
  • Volunteer to participate in clinical research; Fully understand and know the study and sign the informed consent; Willing to follow and able to complete all test procedures.

Exclusion Criteria:

  • Subjects with severe NMOSD were judged by the researcher to be unfit to participate in this study;
  • Subjects with chronic active immune system diseases undergoing systematic treatment;
  • Received anti-CD20 or other cell depletion therapy within 6 months before first dose;
  • Received the prescribed drug treatment at the prescribed time before first dose;
  • Subjects who have participated in any drug clinical trials within 28 days prior to the first dose;
  • Received hematopoietic stem cell transplantation、 lymphatic irradiation before first dose;
  • Pregnant or lactating women; Subjects with birth plans during the trial;
  • Subjects who had undergone major surgery within 2 months prior to screening or were scheduled to undergo major surgery during the trial;
  • Subjects with severe, progressive, or uncontrolled disease who have been assessed by the investigator to be at increased risk of participating in the study;
  • A history of gastrointestinal perforation and/or fistula within 6 months prior to screening;
  • Subjects who received a live or attenuated vaccine within 4 weeks prior to initial administration, or who plan to receive vaccination during the study period;
  • Subjects with severe or persistent infection currently or within the 1 months prior to screening;
  • Subjects with positive gamma interferon release test;
  • Subjects who currently have active hepatitis or have a history of severe liver disease;
  • Uncontrolled systemic disease, or any other reason the investigator deems inappropriate for inclusion;
  • Abnormal laboratory test results;
  • Subjects with a history of alcohol or drug abuse in the 6 months prior to screeing, or who are abusing;
  • Subjects with symptoms of severe mental illness who are clinically uncooperative;
  • Subjects who were unable to undergo magnetic resonance imaging during the study and who had other conditions that the investigator considered inappropriate to enroll.

Quoted from ClinicalTrials.gov, NCT06413654, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06413654, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06413654